Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US0396971071
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG001WH4DQ3
ARDX
Ardelyx Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Ardelyx Inc
ISIN
US0396971071
TICKER
ARDX
MIC
XNAS
REUTERS
ARDX.OQ
BLOOMBERG
ARDX US
Sa., 19.09.2026       Ardelyx
US0396971071

Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ardelyx, Inc. (“Ardelyx” or “the Company”) (NASDAQ: ARDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange C...
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Sa., 19.09.2026       Ardelyx
US0396971071

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ardelyx, Inc. (“Ardelyx” or the “Company”) (NASDAQ: ARDX) and reminds investors of the November 16, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.This press relea...
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Fr., 18.09.2026       Ardelyx
US0396971071

Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Ardelyx, Inc. (NASDAQ: ARDX) common stock between January 13, 2025 and August 6, 2026, inclusive (the "Class Period"). Ardelyx, Inc. develops and commercializes medicines, including ISBRELA fo...
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Di., 01.09.2026       Ardelyx
US0396971071

WALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced its participation in the following investor conferences:...
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Mo., 17.08.2026       Ardelyx
US0396971071

Every 100 shares of Ardelyx (NASDAQ: ARDX) held into August 7, 2026 lost about $87 in value as the stock fell 17.86% to close at $4.00 following the Company's second quarter report. If you held ARDX shares and lost money, you are encouraged to submit your loss information for review. You may also contact Joseph E. Levi, Esq. via email at jlevi@lev...
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Fr., 14.08.2026       Ardelyx
US0396971071

Ardelyx cut its 2026 IBSRELA revenue guidance by up to $80 million on August 6, 2026, citing payer utilization-management restrictions -- and shares fell nearly 18% the next session. NEW YORK, Aug. 14, 2026 /PRNewswire/ -- Payer coverage restrictions allegedly cost Ardelyx (NASDAQ: ARDX) shareholders roughly 18% of their investment on August 7, 2...
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Fr., 14.08.2026       Ardelyx
US0396971071

ARDX closed at $4.00 on August 7, 2026 -- down 17.86% -- after Q2 product revenue of $118.1 million came in below consensus and analysts cut price targets in accord. NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Ardelyx (NASDAQ: ARDX) shares closed at $4.00 on August 7, 2026, an 17.86% single-session decline, after the Company reported second quarter 2...
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Do., 23.07.2026       Ardelyx
US0396971071

Conference call scheduled for 4:30 p.m. Eastern Time Conference call scheduled for 4:30 p.m. Eastern Time...
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Di., 19.05.2026       Ardelyx
US0396971071

WALTHAM, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced its participation in a fireside chat at the Jefferies Global Hea...
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Do., 07.05.2026       Ardelyx
US0396971071

WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced the presentation of a data analysis evaluating the long-term impact of XPHOZAH® (tenapanor)...
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mo., 27.04.2026       Ardelyx
US0396971071

Presentation evaluates the long-term impact of XPHOZAH® on serum electrolytes and select nutrition biomarkers Presentation evaluates the long-term impact of XPHOZAH® on serum electrolytes and select nutrition biomarkers...
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Do., 23.04.2026       Ardelyx
US0396971071

WALTHAM, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced an abstract, exploring the patient characteristics associated with irritable bowel syndrom...
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Do., 16.04.2026       Ardelyx
US0396971071

Conference call scheduled for 4:30 p.m. Eastern Time Conference call scheduled for 4:30 p.m. Eastern Time...
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Mi., 01.04.2026       Ardelyx
US0396971071

WALTHAM, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced the appointment of Rajani Dinavahi, MD, as Chief Medical Officer (CMO). Dr. Dinavahi brings more than two d...
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Mo., 09.03.2026       Ardelyx
US0396971071

Post hoc analysis supports a reduction of time to first bowel movement and a consistent improvement in abdominal symptoms, including pain, discomfort, and bloating, during 12 weeks of treatment Post hoc analysis supports a reduction of time to first bowel movement and a consistent improvement in abdominal symptoms, including pain, discomfort, and b...
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Do., 19.02.2026       Ardelyx
US0396971071

IBSRELA revenue grew 73% in 2025 to $274.2 million and total revenues reached $407.3 million...
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Do., 05.02.2026       Ardelyx
US0396971071

Earnings Teaser Press Release...
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Mo., 26.01.2026       Ardelyx
US0396971071

Issued on behalf of Avant Technologies Inc.Equity Insider News CommentaryVANCOUVER, BC, Jan. 26, 2026 /PRNewswire/ -- The medical world is shifting as the global market for next-gen treatments heads toward $88.85 billion by 2030[1], driven by a surge in funding for high-tech cures for long-term illness. A major FDA move at the beginning of the yea...
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Mo., 26.01.2026       Ardelyx
US0396971071

Issued on behalf of Avant Technologies Inc.Equity Insider News CommentaryVANCOUVER, BC, Jan. 26, 2026 /CNW/ -- The medical world is shifting as the global market for next-gen treatments heads toward $88.85 billion by 2030[1], driven by a surge in funding for high-tech cures for long-term illness. A major FDA move at the beginning of the year[2] is...
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Do., 08.01.2026       Ardelyx
US0396971071

Company achieved significant commercial progress in 2025, generating approximately $378 million in product revenue1 ...
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Fr., 07.11.2025       Ardelyx
US0396971071

WALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the company presented data, including results from the first real-world study...
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Di., 04.11.2025       Ardelyx
US0396971071

WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that President and CEO, Mike Raab will participate in a fireside chat at the Wedbu...
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Di., 28.10.2025       Ardelyx
US0396971071

IBSRELA patients reported treatment satisfaction in real-world survey...
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Mo., 13.10.2025       Ardelyx
US0396971071

Conference call scheduled for 4:30 p.m. Eastern Time Conference call scheduled for 4:30 p.m. Eastern Time...
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Mo., 13.10.2025       Ardelyx
US0396971071

WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of Sue Hohenleitner as Chief Financial Officer (CFO), effective No...
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
So., 22.06.2025       Ardelyx
US0396971071

NEW YORK, June 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Di., 17.06.2025       Ardelyx
US0396971071

NEW YORK, June 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Do., 12.06.2025       Ardelyx
US0396971071

NEW YORK, June 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Sa., 07.06.2025       Ardelyx
US0396971071

NEW YORK, June 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Mo., 02.06.2025       Ardelyx
US0396971071

WALTHAM, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Mike Kelliher, formerly Executive Vice President, Corporate Development and S...
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Mo., 26.05.2025       Ardelyx
US0396971071

NEW YORK, May 26, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Mi., 21.05.2025       Ardelyx
US0396971071

WALTHAM, Mass., May 21, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Mike Raab, President and CEO, will participate in a fireside chat at the Jeffe...
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Di., 20.05.2025       Ardelyx
US0396971071

NEW YORK, May 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Mo., 12.05.2025       Ardelyx
US0396971071

NEW YORK, May 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Mi., 07.05.2025       Ardelyx
US0396971071

NEW YORK, May 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Di., 06.05.2025       Ardelyx
US0396971071

Analysis of IBS in America 2024 Real-World Survey Demonstrates that severity of IBS-C correlates with financial hardship and distress Analysis of IBS in America 2024 Real-World Survey Demonstrates that severity of IBS-C correlates with financial hardship and distress...
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Do., 24.04.2025       Ardelyx
US0396971071

WALTHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the company will present data supporting the company’s first-in-class retain...
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Do., 17.04.2025       Ardelyx
US0396971071

Conference call scheduled for 4:30 p.m. Eastern Time Conference call scheduled for 4:30 p.m. Eastern Time...
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Do., 13.03.2025       Ardelyx
US0396971071

Award established to recognize leaders in the field of chronic kidney disease advocacy Award established to recognize leaders in the field of chronic kidney disease advocacy...
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Mi., 26.02.2025       Ardelyx
US0396971071

Ardelyx to receive $5 million milestone payment from Fosun Pharma following approval Ardelyx to receive $5 million milestone payment from Fosun Pharma following approval...
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Di., 25.02.2025       Ardelyx
US0396971071

WALTHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced its participation in the following upcoming investor conferences:...
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Do., 20.02.2025       Ardelyx
US0396971071

Company achieved significant commercial progress in 2024, finishing with total revenue of $333.6 million, including $319.2 million in U.S. Net Product Sales...
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Mi., 19.02.2025       Ardelyx
US0396971071

WALTHAM, Mass., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that management will present at TD Cowen’s 45th Annual Health Care Conference on M...
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Do., 30.01.2025       Ardelyx
US0396971071

Conference call scheduled for 8:00 a.m. Eastern Time Conference call scheduled for 8:00 a.m. Eastern Time...
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Mo., 13.01.2025       Ardelyx
US0396971071

Company achieved significant commercial progress in 2024, finishing with total U.S. net product sales revenue of approximately $319 million (unaudited)...
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Mi., 20.11.2024       Ardelyx
US0396971071

WALTHAM, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Justin Renz, Chief Financial and Operations Officer, and Eric Foster, Chief C...
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Fr., 08.11.2024       Ardelyx
US0396971071

Inclusion of oral-only phosphate-lowering therapies in the ESRD PPS will put dialysis patients’ health at risk Inclusion of oral-only phosphate-lowering therapies in the ESRD PPS will put dialysis patients’ health at risk...
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Di., 05.11.2024       Ardelyx
US0396971071

WALTHAM, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Michael Raab, President and CEO, Justin Renz, Chief Financial and Operations...
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Mo., 21.10.2024       Ardelyx
US0396971071

Deadline to submit nominations is January 31, 2025 Deadline to submit nominations is January 31, 2025...
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink
Di., 15.10.2024       Ardelyx
US0396971071

New York, New York--(Newsfile Corp. - October 15, 2024) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Ardelyx, Inc. ("Ardelyx" or "the Company") (NASDAQ: ARDX) and certain of its officers.Class DefinitionThis lawsuit seeks to recover damages against...
Zur Nachricht
Ardelyx
Charts & Research Termsheets Terminal
Permalink